Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Lung cancer 2008
3. US incidence of NSCLC by stage (2003)
4. ECOG 1594 study
5. ECOG 1594 survival curve
6. Selected trials of novel agents + chemotherapy
7. ECOG 4599 study: Chemotherapy +/- bevacizumab
8. Bevacizumab - structure
9. Vascular endothelial growth factor
10. The VEGF family
11. Principles of angiogenesis
12. Bevacizumab in NSCLC - ECOG 4599 (1)
13. Bevacizumab in NSCLC: not for everybody
14. Phase II trial of PC with/without bevacizumab
15. PC +/- bevacizumab in metastatic NSCLC
16. Bevacizumab in NSCLC - Hemorrhagic events
17. Example of tumor cavitation following bevacizumab
18. PC +/- bevacizumab - non-squamous subset
19. Bevacizumab in NSCLC - ECOG 4599 (2)
20. Patient characteristics
21. Response rates
22. Progression-free survival by Tx arm
23. Survival by treatment arm
24. Hematologic toxicity
25. Non-hematologic toxicity
26. Treatment related deaths
27. Risk factors associated with bevacizumab
28. E4599: efficacy by gender
29. E4599: efficacy by age
30. Toxicity on PCB arm - elderly vs. non-elderly
31. NCCN practice guidelines in oncology
32. AVAiL: phase III trial of bevacizumab + GC
33. The AVAiL study: objectives
34. The AVAiL study: eligibility
35. The AVAiL study: patient accrual
36. The AVAiL study: demographics
37. Progression-free survival: primary analysis (1)
38. Progression-free survival: primary analysis (2)
39. PFS in subgroups of interest
40. Overall response
41. AVAiL: toxicity
42. AVAiL: conclusions
43. PCB in frontline metastatic NSCLC
44. Bevacizumab in second line therapy
45. Bevacizumab + chemo/erlotinib: RP2
46. Efficacy and safety summary
47. Progression-free survival
48. Adjuvant therapy in NSCLC
49. Lung adjuvant cisplatin evaluation
50. OS by trial
51. Survival curves
52. E1505: phase III trial of adjuvant +/- bevacizumab
53. Broader range safely treated with bevacizumab?
54. The PASSPORT and ATLAS studies
55. Brain metastases in pts receiving bevacizumab (1)
56. Brain metastases in pts receiving bevacizumab (2)
57. Brain metastases in pts receiving bevacizumab (3)
58. Bevacizumab and full dose anti-coagulation
59. AVAiL and FDAC
60. AVAiL and FDAC: conclusions
61. Protocol AVF3744g: BRIDGE trial
62. Primary objective
63. Schema of the BRIDGE study
64. Bevacizumab in small cell lung cancer
65. Bevacizumab in first-line extensive stage small cell
66. Efficacy results
67. Toxicity results
68. Conclusions for chemo with bevacizumab
69. Other VEGF inhibitors
70. VEGFR TKI's
71. Why when we have bevacizumab?
72. Tyrosine kinases within the kinome
73. Signaling pathways as targets in cancer
74. Promising small molecule inhibitors of VEGFR
75. Sorafenib
76. Sorafenib phase II
77. Sorafenib "window of opportunity" study
78. Sorafenib and chemo: phase I subset analysis
79. ESCAPE - phase III trial, CGl +/- sorafenib
80. Overall survival by histology
81. Sunitinib
82. Sunitinib phase II
83. Sunitinib: continuous dosing
84. Vandetanib (ZD6474)
85. Activity of dual VEGF/EGFR inhibition
86. ZD6474 vs. gefitinib (1)
87. Progression-free survival (1)
88. ZD6474 vs. gefitinib (2)
89. Docetaxel +/- ZD6474: phase II study design
90. Progression-free survival (2)
91. Docetaxel +/- ZD6474 in refractory NSCLC
92. Vandetanib with or without CP for first-line NSCLC
93. Progression-free survival (3)
94. Exploratory analysis of PFS - gender
95. Ongoing phase III trials of vandetanib
96. Planned phase III trials for vandetanib
97. Axitinib
98. Axitinib: phase II
99. Axitinib: results
100. Vatalanib
101. Toxicity of small molecular agents
102. VEGFR TKIs and toxicity
103. Efficacy comparison for antiangiogenic agents
104. VEGFR TKIs: conclusions
105. FLEX: a phase III study of cetuximab with CV
106. FLEX : study design
107. FLEX - RR, PFS, TTF
108. FLEX overall survival
109. Overall survival - subset analyses
110. Cetuximab or bevacizumab?
111. Bevacizumab: conclusions
112. Thank you

Topics Covered

• Lung cancer incidence
• Survival by treatment group
• Selected trials of novel agents + chemotherapy
• Bevacizumab
• Vascular Endothelial Growth Factor (VEGF)
• Principles of angiogenesis
• Bevacizumab in NSCLC: not for everybody
• Randomized phase II trial of Paclitaxel/Carboplatin with/without Bevacizumab in NSCLC
• Hemorrhagic events
• Example of tumor cavitation in lung following treatment with chemotherapy and Bevacizumab
• Patient haracteristics
• Response rates
• Hematologic and non-hematologic toxicity
• Treatment related deaths
• Efficacy by gender and age
• NCCN pactice guidelines in oncology-v.2.2008
• AVAiL: phase III trial of Bevacizumab + Gemcitabine and Cisplatin in advanced non|squamous cell NSCLC
• Second line therapy for advanced NSCLC: the role of Bevacizumab
• Adjuvant therapy in NSCLC
• Can a broader range of patients be safely treated with Bevacizumab?
• Protocol AVF3744g: BRIDGE trial
• Bevacizumab in small cell lung cancer
• Other VEGF inhibitors
• Overall survival by histology
• Toxicity of small molecular agents

Links

Series:

• Cancer Therapy

Categories:

• Cancer
• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Oncology

Talk Citation

Evans, T. (2009, January 6). Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 4, 2025, from https://doi.org/10.69645/SXGJ5687.
Export Citation (RIS)

Publication History

• Published on January 6, 2009
• Archived on February 25, 2021

Financial Disclosures

• Dr. Tracey Evans has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.